BOSTON – Results from the largest clinical trial of its kind do not support the use of fish oil supplements—a source of omega-3 fatty acid—to help prevent depression. The findings are published in JAMA by a team led by investigators at Massachusetts General Hospital (MGH) and Brigham and Women’s Hospital (BWH).
Experts have recommended omega-3 supplements for reducing the recurrence of depression in some high-risk patients, but there are no guidelines related to the use of these supplements for preventing depression in the general population. Also, studies on this topic have generated mixed results.
To provide clarity, the Vitamin D and Omega-3 Trial-Depression Endpoint Prevention (VITAL-DEP) was designed to test the potential of daily vitamin D and/or omega-3 supplements for preventing depression. A total of 18,353 adults aged 50 years or older without depression at the start of the trial were randomized to receive vitamin D and/or omega-3 supplements or matching placebos for a median of 5.3 years.
“This study is a significant step. It requires many thousands of people to conduct this type of study of preventing depression in adults—something we call universal prevention—and the participants were taking randomized study pills for between 5 to 7 years on average,” says VITAL-DEP lead investigator and lead author Olivia I. Okereke, MD, MS, director of geriatric psychiatry at MGH and an associate professor of psychiatry at Harvard Medical School. “So, it is rare to see a long-term randomized trial of this kind.”
Okereke and her colleagues observed no net benefit of omega-3 supplements for preventing depression or boosting mood over the course of the study. Equal attention was given to risk of developing a clinical depression at any point and to overall mood scores for the duration of follow-up. While a small increase in risk of a depression was inside the statistical margin of significance, Okereke says “there was no harmful or beneficial effect of omega-3 on overall course of mood during the roughly 5 to 7 years of follow-up.”
“There are still health reasons for some people, under the guidance of their health care providers, to take omega-3 fish oil supplements. For example, these supplements increasingly have been found to have benefits for cardiac disease prevention and treatment of inflammatory conditions, in addition to being used for management of existing depressive disorders in some high-risk patients,” says senior author JoAnn E. Manson, MD, DrPH, chief of the Division of Preventive Medicine at BWH, a professor of medicine at Harvard Medical School, and director of the parent VITAL trial. “However, our findings indicate there is no reason for adults without depression in the general population to take fish oil supplements solely for the purpose of preventing depression or for maintaining a positive mood.”
Other authors include Chirag M. Vyas, MBBS, MPH, David Mischoulon, MD, PhD, Grace Chang, MD, MPH, Nancy R. Cook, ScD, Alison Weinberg, MA, Vadim Bubes, PhD, Trisha Copeland, MS, RD, Georgina Friedenberg, MPH, I-Min Lee, MBBS, ScD, Julie E. Buring, ScD, and Charles F. Reynolds III, MD.
The study was supported by the National Institute of Mental Health.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2021, Mass General was named #5 in the U.S. News & World Report list of “America’s Best Hospitals.”
About Brigham and Women’s Hospital
Brigham and Women’s Hospital, a global leader in creating a healthier world, is a founding member of Mass General Brigham and a teaching affiliate of Harvard Medical School. With more than 1,000 inpatient beds, approximately 60,000 inpatient stays, and 1.7 million outpatient encounters annually, the Brigham’s 2,200 physicians provide expert care in virtually every medical and surgical specialty to patients locally, regionally, and around the world. An international leader in basic, clinical, and translational research, Brigham and Women’s Hospital has nearly 5,000 scientists, including physician-investigators, renowned biomedical researchers and faculty supported by nearly $750 million in funding. The Brigham’s medical preeminence dates back to 1832, and now, with over 20,000 employees, that rich history is the foundation for its commitment to patient care, research, innovation, and community.
Method of Research
Randomized controlled/clinical trial
Subject of Research
Effect of Long-term Supplementation With Marine Omega-3 Fatty Acids vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores
Article Publication Date
Dr Okereke reported receiving royalties from Springer Publishing. Dr Mischoulon reported receiving nonfinancial support from Nordic Naturals and heckel medizintechnik GmbH outside the submitted work; speaking honoraria from the Massachusetts General Hospital Psychiatry Academy; and working with the Massachusetts General Hospital Clinical Trials Network and Institute, which has received research funding from multiple pharmaceutical companies and from the National Institute of Mental Health (NIMH). Dr Manson reported receiving grants from Mars Edge and nonfinancial support from Pronova/BioPharma/BASF. No other disclosures were reported.